Microvast Holdings announces departure of chief financial officer
Tuesday, Envista Holdings Corp . (NYSE:NVST), a healthcare company with $2.51 billion in annual revenue and a robust 55.43% gross profit margin, received a reiterated Hold rating from Needham, as the company prepares to host its Capital Markets Day on March 5, 2025. According to InvestingPro, eight analysts have recently revised their earnings expectations downward for the upcoming period. The event, which is scheduled to take place at the New York Stock Exchange from 9:00 am to 12:00 pm ET, will be Envista’s first since the CEO transition last year.
During the upcoming Capital Markets Day, Envista is expected to outline a strategy aimed at driving long-term value creation. The company will also offer a detailed look into its various business segments, with a particular emphasis on implants and orthodontics. Additionally, Envista is anticipated to announce medium-term financial targets.
Needham analysts predict that Envista’s financial targets will suggest the company is positioned to outgrow the market by 100 basis points. However, there is uncertainty regarding whether management will factor in a market recovery over the medium term. The analysts pointed out that current consensus estimates for 2026-2027 seem to assume a normalized market condition, which poses a risk of downside if the market does not recover as expected, or limited upside if it does.
The Hold rating reflects Needham’s cautious stance on Envista’s stock, taking into account the potential risks and uncertainties associated with market recovery and the company’s ability to meet its growth targets. The stock currently trades near its 52-week high of $23.00, with analyst targets ranging from $18.00 to $26.00. Investors are now looking forward to the Capital Markets Day for further insights into Envista’s strategies and financial goals for the coming years. InvestingPro analysis suggests the stock is slightly undervalued, with additional metrics and insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of what really matters for smarter investing decisions.
In other recent news, Envista Holdings Corp. reported fourth-quarter financial results that exceeded consensus revenue and earnings expectations, though its 2025 guidance did not align with analyst predictions. Following this, Needham analysts maintained a Hold rating on the stock, noting the company’s strong performance in dental implants and the anticipated profitability of its Spark product by late 2025. Meanwhile, Envista announced a stock repurchase program authorizing up to $250 million in buybacks, a move aimed at enhancing shareholder value. Piper Sandler raised Envista’s stock price target to $18, maintaining a Neutral rating, and expressed cautious optimism about the company’s turnaround efforts. In contrast, Mizuho (NYSE:MFG) Securities initiated coverage with an Underperform rating and a $20 price target, citing soft global dental markets and the company’s product mix as challenges. Despite these challenges, Envista’s stock has shown resilience compared to sector peers. Recent executive changes, including a new CEO, are seen as setting the stage for potential earnings growth in the coming years. Analysts will be closely watching Envista’s upcoming Capital Markets Day for further insights into its strategic plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.